Allogeneic perpheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 32, Issue 8, 2003, Pages 763-769

  Seropian, Stuart ^a   Bahceci, E ^a   Cooper, D L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic transplant; Graft versus lymphoma; Non Hodgkin's lymphoma; PBSC

Indexed keywords

ACICLOVIR; BUSULFAN; CARMUSTINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; ENOXAPARIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; INFLIXIMAB; INTERFERON; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID; PENTAMIDINE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; ALLOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RISK FACTOR;

ADULT; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 1642443596     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704233     Document Type: Article

References (28)

1. Chopra R, Goldstone AH, Pearce R et al. Autologous vs allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690-1695.
2. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
3. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
4. Juckett M, Rowlings P, Hessner M et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: Clinical and molecular follow-up. Bone Marrow Transplant 1998; 21: 893-899.
5. Schimmer AD, Jamal S, Messner H et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 2000; 26: 859-864.
6. Toze CL, Shepherd JD, Connors JM et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 605-612.
7. Radich JP, Gooley T, Sanders JE et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272-279.
8. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1836.
9. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859-863.
10. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
11. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
12. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
13. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
14. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
15. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
16. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: Updated results of the Utrecht experience. Leuk Lymphoma 1999; 34: 129-136.
17. Przepiorka D, van Besien K, Khouri I et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999; 10: 527-532.
18. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
19. Przepiorka D, Weisdorf D, Martin P et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
21. Rinder HM, Munz UJ, Ault KA et al. Reticulated platelets in the evaluation of thrombopoietic disorders. Arch Pathol Lab Med 1993; 117: 606-610.
22. Kroger N, Hoffknecht M, Kruger W et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000; 79: 578-580.
23. Martinez C, Carreras E, Rovira M et al. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 2000; 26: 677-679.
24. Sohn SK, Baek JH, Kim DH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: A case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000; 65: 75-80.
25. Khouri IF, Lee MS, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293-1299.
26. Moskowitz CH, Nimer SD, Glassman JR et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 1999; 23: 561-567.
27. Naumann R, Beuthien-Baumann B, Bredow J et al. Positron emission tomography with 18F-FDG in the evaluation of post treatment residual mass in patients with malignant lymphoma. Proc. Amer Soc Hem 2001; 98: 125a.
28. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.